Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 15/20 | 0.49 |
| ▸ | USP2 | O75604 | 12/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 8/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 7/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 6/20 | 0.49 |
| ▸ | TSHR | P16473 | 7/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL484661 | 0.88 | EPHX2 (0.39) | CYP3A4USP2CYP1A2CYP2C9CYP2D6 | |
| SCHEMBL484803 | 0.87 | EPHX2 (0.43) | CYP3A4USP2CYP1A2CYP2C19TSHR | |
| SCHEMBL484533 | 0.87 | EPHX2 (0.42) | CYP3A4USP2CYP1A2CYP2C9CYP2D6 | |
| SCHEMBL484581 | 0.87 | CYP3A4 (0.41) | CYP3A4USP2CYP1A2CYP2C9CYP2D6 | |
| SCHEMBL484850 | 0.85 | CYP3A4 (0.51) | CYP3A4USP2CYP1A2CYP2C9CYP2D6 | |
| SCHEMBL484643 | 0.84 | CYP3A4 (0.46) | CYP3A4USP2CYP1A2CYP2C9CYP2D6 | |
| SCHEMBL2818607 | 0.84 | NAMPT (0.42) | — | |
| SCHEMBL486049 | 0.83 | HSD11B1 (0.39) | — | |
| SCHEMBL484642 | 0.83 | EPHX2 (0.39) | USP2TSHRALDH1A1SMN1; SMN2 | |
| SCHEMBL484408 | 0.82 | EPHX2 (0.39) | CYP3A4USP2CYP1A2CYP2C19TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130231327-A1 | Substituted Spiro-Amide Compounds | GRUENENTHAL GMBH (DE) | 2013-09-05 | — | — | US | claimed |
| US-8455475-B2 | Substituted spiro-amide compounds | GRUENENTHAL GMBH (DE) | 2013-06-04 | — | — | US | claimed |
| EP-2411381-A1 | SUBSTITUTED SPIRO-AMIDE COMPOUNDS | Grünenthal GmbH (DE) | 2012-02-01 | — | — | EP | claimed |
| US-20100249095-A1 | Substituted Spiro-amide Compounds | GRUENENTHAL GMBH (DE) | 2010-09-30 | — | — | US | claimed |
| WO-2010108651-A1 | SUBSTITUTED SPIRO-AMIDE COMPOUNDS | Grünenthal GmbH (DE) | 2010-09-30 | — | — | WO | claimed |
| US-20130231327-A1 | Substituted Spiro-Amide Compounds | GRUENENTHAL GMBH (DE) | 2013-09-05 | — | — | US | disclosed |
| US-8455475-B2 | Substituted spiro-amide compounds | GRUENENTHAL GMBH (DE) | 2013-06-04 | — | — | US | disclosed |
| EP-2411381-A1 | SUBSTITUTED SPIRO-AMIDE COMPOUNDS | Grünenthal GmbH (DE) | 2012-02-01 | — | — | EP | disclosed |
| US-20100249095-A1 | Substituted Spiro-amide Compounds | GRUENENTHAL GMBH (DE) | 2010-09-30 | — | — | US | disclosed |
| WO-2010108651-A1 | SUBSTITUTED SPIRO-AMIDE COMPOUNDS | Grünenthal GmbH (DE) | 2010-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130231327-A1 | Substituted Spiro-Amide Compounds | BDKRB1, BDKRB2, REN | CYP3A4 3781/4885USP2 4864/4885CYP1A2 3400/4885 |
| US-20100249095-A1 | Substituted Spiro-amide Compounds | BDKRB1, BDKRB2, REN | CYP3A4 3781/4885USP2 4864/4885CYP1A2 3400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.